Accelera
Accelera is a Milan-based preclinical CRO specializing in GLP-compliant toxicology, safety pharmacology, DART studies, and oncology efficacy models. It serves over 300 pharmaceutical and biotechnology companies globally, supporting drug development from discovery through marketing authorization across small molecules, biologics, and advanced therapies.
- Company typePrivate
- Founded2009
- HeadquartersNerviano, Italy
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Accelera does
Accelera S.r.l. is a preclinical contract research organization (CRO) headquartered in Nerviano, Greater Milan, Italy, founded in 2009 as the independent CRO unit of Nerviano Medical Sciences (NMS). The company operates from a single site with more than 60 years of pharmaceutical R&D heritage tracing from Farmitalia's pioneering anthracycline research through Pharmacia, Pfizer, and NMS. Accelera delivers GLP-compliant preclinical services across general toxicology, safety pharmacology, developmental and reproductive toxicology (DART), genetic toxicology, carcinogenicity studies, efficacy modeling, biomarker analysis, formulation development, and regulatory consulting, supporting small molecules, biologics, biosimilars, oligonucleotides, and advanced cell and gene therapies from discovery through marketing authorization. Its facilities hold GLP certification and AAALAC accreditation, with data accepted by EMA, FDA, KFDA, and MHLW for regulatory submissions.
The company's service portfolio is organized into three pillars: Drug Development Services spanning Discovery, IND-Enabling, and Post-IND phases; Research Models including over 50 validated cell line-derived xenograft (CDX), syngeneic, humanized, orthotopic, bioluminescent, and genetically modified mouse models; and operational capabilities including SEND data generation, anatomic and clinical pathology, project management, GLP-compliant archiving, and safety/regulatory strategy. Notable technical components include validated ELISA and multiplex immunoassay biomarker platforms, integrated telemetry platforms for cardiovascular, pulmonary, and nervous system safety assessments, and IVIS-based bioluminescent imaging for orthotopic models. Accelera has completed over 100 GLP-compliant DART studies since 2010 and serves more than 300 pharmaceutical and biotechnology customers in Europe, the US, and South Korea.
Accelera operates a fee-for-service business model with custom quote-based pricing and multi-year contract structures, generating revenue through fee-for-service contract research agreements rather than product sales. Its go-to-market combines direct enterprise sales, inside sales through website inquiries, strategic partnering programs, and active participation at major industry events including BIO Europe, BIO International Convention, Swiss Biotech Day, BioTrinity, LSX Nordic Congress, German Biotech Days, NLS Days, and BIO-Europe Spring. The company targets large pharmaceutical enterprises alongside resource-constrained small biotechs, startups, and academic institutions. Accelera is a wholly-owned subsidiary of NMS Group S.p.A. with no disclosed external institutional or venture capital backing.
Accelera firmographics
Firmographics- Name
- Accelera
- Legal name
- Accelera S.r.l.
- Website
- https://accelera.org
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Accelera is a Milan-based preclinical CRO specializing in GLP-compliant toxicology, safety pharmacology, DART studies, and oncology efficacy models. It serves over 300 pharmaceutical and biotechnology companies globally, supporting drug development from discovery through marketing authorization across small molecules, biologics, and advanced therapies.
- Ownership category
- akta.pro rank
Accelera industry classification
Industry- Product category
- Preclinical Contract Research Services
- NAICS
- Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)
- akta.pro secondary industries
- Preclinical CROs (Discovery/Pharmacology/DMPK) (HLAGAAAB), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)
Keywords
Where Accelera is headquartered
LocationHeadquarters
- HQ city
- Nerviano
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
Accelera business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Revenue model
- Contract Research Services: Accelera generates revenue through fee-for-service contract research agreements providing preclinical toxicology, safety pharmacology, efficacy studies, and regulatory consulting services to pharmaceutical and biotech companies. Services range from early discovery through IND-enabling packages to post-IND programs for marketing authorization.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom project-based pricing tailored to client requirements |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Accelera product offering
Product offeringCore offering
Accelera is a Contract Research Organization (CRO) that provides integrated preclinical drug development services from early discovery through IND-enabling studies and post-IND programs. Its portfolio covers general and specialized toxicology, safety pharmacology, genetic toxicology, developmental and reproductive toxicology (DART), carcinogenicity studies, efficacy models for oncology, bioanalytical/biomarker analysis, formulation development, and regulatory consulting. Services are delivered under GLP and AAALAC standards recognized by EMA, FDA, KFDA, and MHLW, supporting small molecules, biologics, biosimilars, oligonucleotides, and advanced cell and gene therapies.
Product overview
Accelera is a premium-tier Contract Research Organization (CRO) based in Milan, Italy, providing integrated preclinical drug development services. The company's portfolio spans three core areas: Drug Development Services (encompassing Discovery, IND-Enabling, and Post-IND phases), Research Models (including CDX, Syngeneic, Humanized, Orthotopic/Bioluminescent, and Genetically Modified models), and Capabilities (Scientific, Strategic, and Operational). Services include general toxicology, DART studies, safety pharmacology, genetic toxicology, biomarkers, efficacy models, formulation development, and regulatory consulting. The integrated platform supports small molecules, biologics, and advanced therapies (cell and gene therapy) from early discovery through marketing authorization, serving over 300 global pharmaceutical and biotechnology companies.
Differentiator
Problem solved
Functional benefit
Products and services
- Target Safety Assessment Structured evaluation of biological safety profiles of drug targets early in discovery, combining literature review, genetic and pathway analysis, and translational insight to identify potential safety risks before program progression.
Quantifiable outcome
- >100 GLP-compliant DART studies completed since 2010
- +2 more outcomes
Companies that use Accelera
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Accelera technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Accelera partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- DNDi (Drugs for Neglected Diseases initiative)coreKey partnership with DNDi, an international non-profit drug research and development organization, to advance treatments for neglected diseases. Accelera provides preclinical expertise as part of collaborative efforts to develop new therapies.
- CellectiscorePartnership with Cellectis, a clinical-stage biopharmaceutical company focused on oncology, leveraging Accelera's preclinical capabilities for advanced therapy development.
- Karolinska InstitutetcoreCollaborative partnership with Karolinska Institutet, one of Europe's largest and most prestigious medical universities, for research and development initiatives in drug discovery and development.
- NMS Group S.p.A.coreAccelera Srl is part of NMS Group S.p.A. along with Nerviano Medical Sciences S.r.l., NerPharMa S.r.l., and SIMIS S.r.l. The NMS Group provides direction and control, with Accelera operating as the CRO unit offering third-party preclinical services.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Accelera competitors and assessment
Company assessmentBroad incumbents
- ICON plc: Global CRO with preclinical and clinical safety capabilities through acquisitions. While primarily clinical, ICON's preclinical safety and laboratory services overlap with Accelera's offerings for integrated sponsors.
- Eurofins Scientific: Large testing and CRO group with preclinical safety and toxicology service lines in Europe. Competes with Accelera for European biotech preclinical work, particularly for sponsors seeking broad lab services alongside toxicology.
- WuXi AppTec: Global CRO/CDMO offering preclinical toxicology and safety assessment as part of a broader integrated discovery-to-manufacturing platform. Competes with Accelera on preclinical study execution, particularly for biotech clients seeking integrated services.
- Labcorp Drug Development (formerly Covance): Major CRO providing preclinical toxicology and safety assessment services alongside broad clinical and central lab offerings. Direct competitor for preclinical safety work, with substantially larger scale and global footprint.
- Charles River Laboratories: Global CRO with a leading preclinical and safety assessment division that competes with Accelera in GLP toxicology, DART, and safety pharmacology. Far larger and broader, but Accelera competes on boutique attention and specialty oncology/advanced-therapy expertise.
Direct peers
- Inotiv: Preclinical CRO focused on toxicology, safety assessment, and research models, with a similar specialized niche to Accelera including DART and safety pharmacology capabilities. Highly relevant direct competitor for boutique preclinical services.
- Celerion: Specialized CRO offering preclinical and early clinical services including bioanalytical and clinical pharmacology. Comparable in scale and boutique positioning to Accelera, particularly attractive to small biotech sponsors.
- Toxikon: Preclinical CRO specialized inGLP toxicology, medical device, and pharmaceutical safety studies. Comparable boutique CRO competing with Accelera in preclinical safety assessment, particularly for North American sponsors.
- SGS Life Sciences: Global CRO offering preclinical toxicology, safety pharmacology, and bioanalytical services with GLP accreditation. Highly comparable to Accelera in service mix and customer base, particularly in European preclinical safety.
Emerging players
- Pharmaron: Integrated CRO/CDMO with growing preclinical toxicology and safety assessment capabilities in the UK, China, and US. Overlaps with Accelera on preclinical services and competes for biotech and emerging pharma sponsors.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Accelera social profiles
Digital presenceAccelera compliance and trust
Trust signalCompliance9 records
Accelera financial estimates
Financial estimateRevenue estimate
Valuation estimate
Accelera leadership team
Management profileNumber of profiles
Profiles1 record
Accelera funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Accelera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Accelera
What does Accelera do?
Accelera is a Contract Research Organization (CRO) that provides integrated preclinical drug development services from early discovery through IND-enabling studies and post-IND programs. Its portfolio covers general and specialized toxicology, safety pharmacology, genetic toxicology, developmental and reproductive toxicology (DART), carcinogenicity studies, efficacy models for oncology, bioanalytical/biomarker analysis, formulation development, and regulatory consulting. Services are delivered under GLP and AAALAC standards recognized by EMA, FDA, KFDA, and MHLW, supporting small molecules, biologics, biosimilars, oligonucleotides, and advanced cell and gene therapies.
Is Accelera a public or private company?
Accelera is a private company. It is classified as corporate owned and is currently operating.
When was Accelera founded?
Accelera was founded in 2009. It employs 51 to 100 people.
Where is Accelera based?
Accelera is headquartered in Nerviano, Italy, in the Europe region.
How does Accelera make money?
One revenue line is on record: contract Research Services.
Who are Accelera's main competitors?
Broad incumbents on record are ICON plc, Eurofins Scientific, WuXi AppTec, Labcorp Drug Development (formerly Covance) and Charles River Laboratories. Direct peers are Inotiv, Celerion, Toxikon and SGS Life Sciences. Pharmaron is listed as an emerging player.
Does Accelera have an API?
No public API is recorded for Accelera.
What industry is Accelera in?
Accelera's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 5417 and its SIC code is 8731.